In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Anaplastic thyroid cancer (ATC) is a rare malignancy. While external beam radiation therapy
has improved locoregional control, the median survival of∼ 4 months has not changed in …

Background: Vitamin C has been demonstrated to kill BRAF mutant colorectal cancer cells
selectively. BRAF mutation is the most common genetic alteration in thyroid tumor …

The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator
(NCOA) 2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are key pleiotropic …

Abstract BRAF (V600E) mutation is the most frequent genetic alteration in papillary thyroid
carcinomas (PTCs) that are 80–90% of all thyroid cancers. We evaluated the relationship …

Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–
90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein …

Advanced differentiated thyroid cancer (DTC), defined by clinical characteristics including
gross extrathyroidal invasion, distant metastases, radioiodine (RAI) resistance, and avidity …

Thyroid gland presents a wide spectrum of tumours derived from follicular cells that range
from well differentiated, papillary and follicular carcinoma (PTC and FTC, respectively) …

Background Molecular alterations of the MAPK pathway are frequently observed in papillary
thyroid carcinomas (PTCs). It leads to a constitutive activation of the signalling pathway …

Somatic activating mutations in the B-Raf kinase (BRAF mutations) are present in hairy-cell
leukemia, cutaneous melanoma, thyroid carcinomas and, less commonly, in ovarian, colon …